0000000000587740

AUTHOR

Marina Talamonti

showing 6 related works from this author

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

2021

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severi…

Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusiness
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Additional file 1 of A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA obs…

2021

Additional file 1.

Data_FILES
researchProduct